ID   APAF_HUMAN              Reviewed;        1248 AA.
AC   O14727; B2RMX8; O43297; Q7Z438; Q9BXZ6; Q9UBZ5; Q9UGN8; Q9UGN9;
AC   Q9UGP0; Q9UJ58; Q9UJ59; Q9UJ60; Q9UJ61; Q9UJ62; Q9UJ63; Q9UJ64;
AC   Q9UJ65; Q9UJ66; Q9UJ67; Q9UNC9;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2002, sequence version 2.
DT   31-MAY-2011, entry version 137.
DE   RecName: Full=Apoptotic protease-activating factor 1;
DE            Short=APAF-1;
GN   Name=APAF1; Synonyms=KIAA0413;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Cervix carcinoma;
RX   MEDLINE=97410306; PubMed=9267021; DOI=10.1016/S0092-8674(00)80501-2;
RA   Zou H., Henzel W.J., Liu X., Lutschg A., Wang X.;
RT   "Apaf-1, a human protein homologous to C. elegans CED-4, participates
RT   in cytochrome c-dependent activation of caspase-3.";
RL   Cell 90:405-413(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 4 AND 5).
RC   TISSUE=Cervix carcinoma, Heart, and Peripheral blood;
RX   MEDLINE=99373149; PubMed=10441496; DOI=10.1006/bbrc.1999.1124;
RA   Hahn C., Hirsch B., Jahnke D., Duerkop H., Stein H.;
RT   "Three new types of Apaf-1 in mammalian cells.";
RL   Biochem. Biophys. Res. Commun. 261:746-749(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=T-cell;
RX   MEDLINE=99292765; PubMed=10364241; DOI=10.1074/jbc.274.25.17941;
RA   Saleh A., Srinivasula S.M., Acharya S., Fishel R., Alnemri E.S.;
RT   "Cytochrome c and dATP-mediated oligomerization of Apaf-1 is a
RT   prerequisite for procaspase-9 activation.";
RL   J. Biol. Chem. 274:17941-17945(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, SUBUNIT, AND
RP   MUTAGENESIS OF LYS-160 AND MET-368.
RC   TISSUE=Kidney;
RX   MEDLINE=99321747; PubMed=10393175; DOI=10.1093/emboj/18.13.3586;
RA   Hu Y., Benedict M.A., Ding L., Nunez G.;
RT   "Role of cytochrome c and dATP/ATP hydrolysis in Apaf-1-mediated
RT   caspase-9 activation and apoptosis.";
RL   EMBO J. 18:3586-3595(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 6), FUNCTION, AND
RP   SUBCELLULAR LOCATION.
RC   TISSUE=Prostatic carcinoma;
RX   MEDLINE=22688499; PubMed=12804598; DOI=10.1016/S0006-291X(03)00995-1;
RA   Ogawa T., Shiga K., Hashimoto S., Kobayashi T., Horii A., Furukawa T.;
RT   "APAF-1-ALT, a novel alternative splicing form of APAF-1, potentially
RT   causes impeded ability of undergoing DNA damage-induced apoptosis in
RT   the LNCaP human prostate cancer cell line.";
RL   Biochem. Biophys. Res. Commun. 306:537-543(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RX   MEDLINE=98116655; PubMed=9455477; DOI=10.1093/dnares/4.5.307;
RA   Ishikawa K., Nagase T., Nakajima D., Seki N., Ohira M., Miyajima N.,
RA   Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. VIII.
RT   78 new cDNA clones from brain which code for large proteins in
RT   vitro.";
RL   DNA Res. 4:307-313(1997).
RN   [7]
RP   SEQUENCE REVISION.
RX   MEDLINE=22158633; PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 810-864 AND 866-883.
RA   Roberts D.L., Dalgleish R., Cohen G.M., MacFarlane M.;
RT   "The mammalian CED4 homologue, APAF1, exists as two distinct forms in
RT   human cells.";
RL   Submitted (MAR-1999) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-138 (ISOFORMS 1/4/5).
RA   Won M., Lee J.-W., Ohr H.-H., Kim D.-U., Chung K.-S., Lee M.,
RA   Yoo H.-S.;
RT   "Cloning of variant Apaf1.";
RL   Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   APAF-1-MEDIATED OLIGOMERIZATION.
RX   MEDLINE=98315378; PubMed=9651578; DOI=10.1016/S1097-2765(00)80095-7;
RA   Srinivasula S.M., Ahmad M., Fernandes-Alnemri T., Alnemri E.S.;
RT   "Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization.";
RL   Mol. Cell 1:949-957(1998).
RN   [13]
RP   INDUCTION BY E2F AND TP53.
RX   MEDLINE=21283226; PubMed=11389439; DOI=10.1038/35078527;
RA   Moroni M.C., Hickman E.S., Denchi E.L., Caprara G., Colli E.,
RA   Cecconi F., Mueller H., Helin K.;
RT   "Apaf-1 is a transcriptional target for E2F and p53.";
RL   Nat. Cell Biol. 3:552-558(2001).
RN   [14]
RP   INTERACTION WITH APIP.
RX   PubMed=15262985; DOI=10.1074/jbc.M405747200;
RA   Cho D.-H., Hong Y.-M., Lee H.-J., Woo H.-N., Pyo J.-O., Mak T.W.,
RA   Jung Y.-K.;
RT   "Induced inhibition of ischemic/hypoxic injury by APIP, a novel Apaf-
RT   1-interacting protein.";
RL   J. Biol. Chem. 279:39942-39950(2004).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-204; SER-238 AND
RP   SER-248, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (1.3 ANGSTROMS) OF 1-97.
RX   MEDLINE=20013059; PubMed=10543941; DOI=10.1006/jmbi.1999.3177;
RA   Vaughn D.E., Rodriguez J., Lazebnik Y., Joshua-Tor L.;
RT   "Crystal structure of Apaf-1 caspase recruitment domain: an alpha-
RT   helical Greek key fold for apoptotic signaling.";
RL   J. Mol. Biol. 293:439-447(1999).
RN   [17]
RP   STRUCTURE BY NMR OF 1-97.
RX   MEDLINE=20047184; PubMed=10578182; DOI=10.1038/sj.cdd.4400584;
RA   Day C.L., Dupont C., Lackmann M., Vaux D.L., Hinds M.G.;
RT   "Solution structure and mutagenesis of the caspase recruitment domain
RT   (CARD) from Apaf-1.";
RL   Cell Death Differ. 6:1125-1132(1999).
CC   -!- FUNCTION: Oligomeric Apaf-1 mediates the cytochrome c-dependent
CC       autocatalytic activation of pro-caspase-9 (Apaf-3), leading to the
CC       activation of caspase-3 and apoptosis. This activation requires
CC       ATP. Isoform 6 is less effective in inducing apoptosis.
CC   -!- SUBUNIT: Monomer. Oligomerizes upon binding of cytochrome c and
CC       dATP. Oligomeric Apaf-1 and pro-caspase-9 bind to each other via
CC       their respective NH2-terminal CARD domains and consecutively
CC       mature caspase-9 is released from the complex. Pro-caspase-3 is
CC       recruited into the Apaf-1-pro-caspase-9 complex via interaction
CC       with pro-caspase-9. Interacts with APIP.
CC   -!- INTERACTION:
CC       P55211:CASP9; NbExp=2; IntAct=EBI-446492, EBI-516799;
CC       P99999:CYCS; NbExp=2; IntAct=EBI-446492, EBI-446479;
CC       P62136:PPP1CA; NbExp=2; IntAct=EBI-446492, EBI-357253;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC       Name=1; Synonyms=Apaf-1XL;
CC         IsoId=O14727-1; Sequence=Displayed;
CC       Name=2; Synonyms=Apaf-1L;
CC         IsoId=O14727-2; Sequence=VSP_006759;
CC       Name=3; Synonyms=Apaf-1S;
CC         IsoId=O14727-3; Sequence=VSP_006759, VSP_006761;
CC       Name=4; Synonyms=Apaf-1M;
CC         IsoId=O14727-4; Sequence=VSP_006761;
CC       Name=5; Synonyms=Apaf-1XS;
CC         IsoId=O14727-5; Sequence=VSP_006760, VSP_006761, VSP_006762;
CC       Name=6; Synonyms=Apaf-1-ALT;
CC         IsoId=O14727-6; Sequence=VSP_008965, VSP_008966;
CC   -!- TISSUE SPECIFICITY: Ubiquitous. Highest levels of expression in
CC       adult spleen and peripheral blood leukocytes, and in fetal brain,
CC       kidney and lung. Isoform 1 is expressed in heart, kidney and
CC       liver.
CC   -!- INDUCTION: By E2F and p53/TP53 in apoptotic neurons.
CC   -!- DOMAIN: The CARD domain mediates interaction with APIP.
CC   -!- SIMILARITY: Contains 1 CARD domain.
CC   -!- SIMILARITY: Contains 1 NB-ARC domain.
CC   -!- SIMILARITY: Contains 13 WD repeats.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAK28401.1; Type=Frameshift; Positions=108;
CC       Sequence=BAA24843.2; Type=Erroneous initiation;
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/APAF1ID422.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF013263; AAC51678.1; -; mRNA.
DR   EMBL; AJ243003; CAB55579.1; -; mRNA.
DR   EMBL; AJ243004; CAB55580.1; -; mRNA.
DR   EMBL; AJ243005; CAB55581.1; -; mRNA.
DR   EMBL; AJ243006; CAB55582.1; -; mRNA.
DR   EMBL; AJ243007; CAB55583.1; -; mRNA.
DR   EMBL; AJ243008; CAB55584.1; -; mRNA.
DR   EMBL; AJ243009; CAB55585.1; -; mRNA.
DR   EMBL; AJ243010; CAB55586.1; -; mRNA.
DR   EMBL; AJ243011; CAB55587.1; -; mRNA.
DR   EMBL; AJ243048; CAB55588.1; -; mRNA.
DR   EMBL; AJ243107; CAB56462.1; -; mRNA.
DR   EMBL; AF134397; AAD38344.1; -; mRNA.
DR   EMBL; AF149794; AAD34016.1; -; mRNA.
DR   EMBL; AB007873; BAA24843.2; ALT_INIT; mRNA.
DR   EMBL; AB103079; BAC77343.1; -; mRNA.
DR   EMBL; CH471054; EAW97606.1; -; Genomic_DNA.
DR   EMBL; BC136531; AAI36532.1; -; mRNA.
DR   EMBL; BC136532; AAI36533.1; -; mRNA.
DR   EMBL; AJ133643; CAB65085.1; -; Genomic_DNA.
DR   EMBL; AJ133644; CAB65086.1; -; Genomic_DNA.
DR   EMBL; AJ133645; CAB65087.1; -; Genomic_DNA.
DR   EMBL; AF248734; AAK28401.1; ALT_FRAME; mRNA.
DR   IPI; IPI00023630; -.
DR   IPI; IPI00217460; -.
DR   IPI; IPI00217461; -.
DR   IPI; IPI00217462; -.
DR   IPI; IPI00217463; -.
DR   IPI; IPI00375875; -.
DR   PIR; T03818; T03818.
DR   RefSeq; NP_001151.1; NM_001160.2.
DR   RefSeq; NP_037361.1; NM_013229.2.
DR   RefSeq; NP_863651.1; NM_181861.1.
DR   RefSeq; NP_863658.1; NM_181868.1.
DR   RefSeq; NP_863659.1; NM_181869.1.
DR   UniGene; Hs.728891; -.
DR   PDB; 1C15; NMR; -; A=1-97.
DR   PDB; 1CWW; NMR; -; A=1-97.
DR   PDB; 1CY5; X-ray; 1.30 A; A=1-97.
DR   PDB; 1Z6T; X-ray; 2.21 A; A/B/C/D=1-591.
DR   PDB; 2P1H; X-ray; 1.59 A; A=1-92.
DR   PDB; 2YGS; X-ray; 1.60 A; A=1-92.
DR   PDB; 3IZA; EM; -; A/B/C/D/E/F/G=1-1248.
DR   PDB; 3YGS; X-ray; 2.50 A; C=1-95.
DR   PDBsum; 1C15; -.
DR   PDBsum; 1CWW; -.
DR   PDBsum; 1CY5; -.
DR   PDBsum; 1Z6T; -.
DR   PDBsum; 2P1H; -.
DR   PDBsum; 2YGS; -.
DR   PDBsum; 3IZA; -.
DR   PDBsum; 3YGS; -.
DR   ProteinModelPortal; O14727; -.
DR   SMR; O14727; 1-586.
DR   DIP; DIP-27624N; -.
DR   IntAct; O14727; 13.
DR   MINT; MINT-96751; -.
DR   STRING; O14727; -.
DR   PhosphoSite; O14727; -.
DR   PRIDE; O14727; -.
DR   Ensembl; ENST00000359972; ENSP00000353059; ENSG00000120868.
DR   GeneID; 317; -.
DR   KEGG; hsa:317; -.
DR   UCSC; uc001tfy.1; human.
DR   UCSC; uc001tfz.1; human.
DR   UCSC; uc001tga.1; human.
DR   UCSC; uc001tgb.1; human.
DR   UCSC; uc001tgc.1; human.
DR   CTD; 317; -.
DR   GeneCards; GC12P096100; -.
DR   HGNC; HGNC:576; APAF1.
DR   HPA; HPA031373; -.
DR   MIM; 602233; gene.
DR   neXtProt; NX_O14727; -.
DR   PharmGKB; PA24868; -.
DR   eggNOG; prNOG10244; -.
DR   GeneTree; ENSGT00600000084025; -.
DR   HOVERGEN; HBG018730; -.
DR   InParanoid; O14727; -.
DR   OMA; SSYDYEA; -.
DR   OrthoDB; EOG43TZTP; -.
DR   PhylomeDB; O14727; -.
DR   Pathway_Interaction_DB; caspase_pathway; Caspase cascade in apoptosis.
DR   Pathway_Interaction_DB; hivnefpathway; HIV-1 Nef: Negative effector of Fas and TNF-alpha.
DR   Pathway_Interaction_DB; p75ntrpathway; p75(NTR)-mediated signaling.
DR   Reactome; REACT_578; Apoptosis.
DR   DrugBank; DB00171; Adenosine triphosphate.
DR   NextBio; 1287; -.
DR   PMAP-CutDB; O14727; -.
DR   ArrayExpress; O14727; -.
DR   Bgee; O14727; -.
DR   Genevestigator; O14727; -.
DR   GermOnline; ENSG00000120868; Homo sapiens.
DR   GO; GO:0005829; C:cytosol; EXP:Reactome.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:HPA.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0008656; F:caspase activator activity; NAS:UniProtKB.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0008635; P:activation of caspase activity by cytochrome c; IDA:UniProtKB.
DR   GO; GO:0006952; P:defense response; IEA:InterPro.
DR   GO; GO:0008629; P:induction of apoptosis by intracellular signals; TAS:Reactome.
DR   GO; GO:0007399; P:nervous system development; TAS:ProtInc.
DR   InterPro; IPR017251; Apoptotic_pept-activating_1.
DR   InterPro; IPR001315; CARD.
DR   InterPro; IPR011029; DEATH-like.
DR   InterPro; IPR000767; Disease_R.
DR   InterPro; IPR020472; G-protein_beta_WD-40_rep.
DR   InterPro; IPR002182; NB-ARC.
DR   InterPro; IPR015943; WD40/YVTN_repeat-like_dom.
DR   InterPro; IPR001680; WD40_repeat.
DR   InterPro; IPR011046; WD40_repeat-like_dom.
DR   InterPro; IPR019782; WD40_repeat_2.
DR   InterPro; IPR019775; WD40_repeat_CS.
DR   InterPro; IPR017986; WD40_repeat_dom.
DR   InterPro; IPR019781; WD40_repeat_subgr.
DR   Gene3D; G3DSA:1.10.533.10; DEATH_like; 1.
DR   Gene3D; G3DSA:2.130.10.10; WD40/YVTN_repeat-like; 2.
DR   Pfam; PF00619; CARD; 1.
DR   Pfam; PF00931; NB-ARC; 1.
DR   Pfam; PF00400; WD40; 10.
DR   PIRSF; PIRSF037646; Apop_pept_activating-1; 1.
DR   PRINTS; PR00364; DISEASERSIST.
DR   PRINTS; PR00320; GPROTEINBRPT.
DR   SMART; SM00320; WD40; 13.
DR   SUPFAM; SSF47986; DEATH_like; 1.
DR   SUPFAM; SSF50978; WD40_like; 2.
DR   PROSITE; PS50209; CARD; 1.
DR   PROSITE; PS00678; WD_REPEATS_1; 4.
DR   PROSITE; PS50082; WD_REPEATS_2; 9.
DR   PROSITE; PS50294; WD_REPEATS_REGION; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; ATP-binding;
KW   Complete proteome; Cytoplasm; Direct protein sequencing;
KW   Nucleotide-binding; Phosphoprotein; Repeat; WD repeat.
FT   CHAIN         1   1248       Apoptotic protease-activating factor 1.
FT                                /FTId=PRO_0000050844.
FT   DOMAIN        1     90       CARD.
FT   DOMAIN      104    415       NB-ARC.
FT   REPEAT      613    652       WD 1.
FT   REPEAT      655    694       WD 2.
FT   REPEAT      697    738       WD 3.
FT   REPEAT      741    780       WD 4.
FT   REPEAT      796    836       WD 5.
FT   REPEAT      838    877       WD 6.
FT   REPEAT      880    919       WD 7.
FT   REPEAT      959    998       WD 8.
FT   REPEAT     1001   1040       WD 9.
FT   REPEAT     1042   1080       WD 10.
FT   REPEAT     1083   1122       WD 11.
FT   REPEAT     1125   1164       WD 12.
FT   REPEAT     1175   1212       WD 13.
FT   NP_BIND     154    161       ATP (Potential).
FT   COMPBIAS     95     98       Poly-Ser.
FT   MOD_RES     204    204       Phosphothreonine.
FT   MOD_RES     238    238       Phosphoserine.
FT   MOD_RES     248    248       Phosphoserine.
FT   VAR_SEQ      99    109       Missing (in isoform 2 and isoform 3).
FT                                /FTId=VSP_006759.
FT   VAR_SEQ     319    338       GSPLVVSLIGALLRDFPNRW -> VVERCHWGILTDLLHKW
FT                                NQS (in isoform 6).
FT                                /FTId=VSP_008965.
FT   VAR_SEQ     339   1248       Missing (in isoform 6).
FT                                /FTId=VSP_008966.
FT   VAR_SEQ     575    575       E -> ETLGFESKK (in isoform 5).
FT                                /FTId=VSP_006760.
FT   VAR_SEQ     824    866       Missing (in isoform 3, isoform 4 and
FT                                isoform 5).
FT                                /FTId=VSP_006761.
FT   VAR_SEQ    1113   1154       Missing (in isoform 5).
FT                                /FTId=VSP_006762.
FT   MUTAGEN     160    160       K->R: No association with APAF-1. No
FT                                binding to pro-caspase-9.
FT   MUTAGEN     368    368       M->L: Activation of pro-caspase-9
FT                                independent of cytochrome c. Increased
FT                                ability to induce apoptosis.
FT   CONFLICT    134    134       N -> S (in Ref. 11).
FT   CONFLICT    145    145       G -> C (in Ref. 2; CAB55587).
FT   CONFLICT    161    161       S -> F (in Ref. 2; CAB55586).
FT   CONFLICT    370    370       I -> T (in Ref. 2; CAB55581).
FT   CONFLICT    383    383       Y -> H (in Ref. 2; CAB55586).
FT   CONFLICT    544    544       F -> L (in Ref. 2; CAB55584).
FT   CONFLICT    580    580       A -> T (in Ref. 2; CAB55580).
FT   CONFLICT    608    608       R -> C (in Ref. 2; CAB55585).
FT   CONFLICT    620    620       H -> R (in Ref. 2; CAB55587).
FT   CONFLICT    639    639       L -> F (in Ref. 2; CAB55583).
FT   CONFLICT    708    708       T -> A (in Ref. 2; CAB55579).
FT   CONFLICT    742    742       H -> R (in Ref. 2; CAB55584).
FT   CONFLICT    746    746       V -> A (in Ref. 2; CAB55586).
FT   CONFLICT    757    757       L -> P (in Ref. 2; CAB56462).
FT   CONFLICT    795    795       E -> G (in Ref. 2; CAB55581).
FT   CONFLICT    798    798       E -> G (in Ref. 2; CAB55587).
FT   CONFLICT    825    825       D -> A (in Ref. 2; CAB55585).
FT   CONFLICT    871    871       S -> L (in Ref. 2; CAB55587).
FT   CONFLICT    876    876       A -> T (in Ref. 2; CAB55581).
FT   CONFLICT    949    949       I -> V (in Ref. 2; CAB55585).
FT   CONFLICT   1008   1008       H -> R (in Ref. 2; CAB55582).
FT   CONFLICT   1056   1056       S -> P (in Ref. 2; CAB55582).
FT   CONFLICT   1241   1241       L -> I (in Ref. 6; BAA24843).
FT   HELIX         3     11
FT   HELIX        13     19
FT   HELIX        22     32
FT   HELIX        37     44
FT   STRAND       46     48
FT   HELIX        49     61
FT   HELIX        65     77
FT   HELIX        81     87
FT   HELIX        88     90
FT   HELIX       108    116
FT   HELIX       130    140
FT   STRAND      148    153
FT   HELIX       160    168
FT   HELIX       171    177
FT   STRAND      182    189
FT   HELIX       192    206
FT   HELIX       220    233
FT   STRAND      239    245
FT   HELIX       248    252
FT   STRAND      259    265
FT   HELIX       267    270
FT   STRAND      277    281
FT   HELIX       288    299
FT   HELIX       303    305
FT   HELIX       309    316
FT   TURN        317    319
FT   HELIX       321    333
FT   HELIX       338    346
FT   HELIX       362    373
FT   TURN        377    379
FT   HELIX       380    385
FT   HELIX       386    388
FT   HELIX       397    404
FT   HELIX       408    420
FT   STRAND      423    429
FT   STRAND      432    436
FT   HELIX       439    448
FT   HELIX       450    452
FT   HELIX       453    464
FT   TURN        465    467
FT   HELIX       470    472
FT   HELIX       480    493
FT   HELIX       497    504
FT   HELIX       507    517
FT   HELIX       520    528
FT   HELIX       530    532
FT   HELIX       535    550
FT   TURN        551    556
FT   HELIX       563    567
FT   HELIX       575    585
SQ   SEQUENCE   1248 AA;  141840 MW;  0750D05817AC9B3B CRC64;
     MDAKARNCLL QHREALEKDI KTSYIMDHMI SDGFLTISEE EKVRNEPTQQ QRAAMLIKMI
     LKKDNDSYVS FYNALLHEGY KDLAALLHDG IPVVSSSSGK DSVSGITSYV RTVLCEGGVP
     QRPVVFVTRK KLVNAIQQKL SKLKGEPGWV TIHGMAGCGK SVLAAEAVRD HSLLEGCFPG
     GVHWVSVGKQ DKSGLLMKLQ NLCTRLDQDE SFSQRLPLNI EEAKDRLRIL MLRKHPRSLL
     ILDDVWDSWV LKAFDSQCQI LLTTRDKSVT DSVMGPKYVV PVESSLGKEK GLEILSLFVN
     MKKADLPEQA HSIIKECKGS PLVVSLIGAL LRDFPNRWEY YLKQLQNKQF KRIRKSSSYD
     YEALDEAMSI SVEMLREDIK DYYTDLSILQ KDVKVPTKVL CILWDMETEE VEDILQEFVN
     KSLLFCDRNG KSFRYYLHDL QVDFLTEKNC SQLQDLHKKI ITQFQRYHQP HTLSPDQEDC
     MYWYNFLAYH MASAKMHKEL CALMFSLDWI KAKTELVGPA HLIHEFVEYR HILDEKDCAV
     SENFQEFLSL NGHLLGRQPF PNIVQLGLCE PETSEVYQQA KLQAKQEVDN GMLYLEWINK
     KNITNLSRLV VRPHTDAVYH ACFSEDGQRI ASCGADKTLQ VFKAETGEKL LEIKAHEDEV
     LCCAFSTDDR FIATCSVDKK VKIWNSMTGE LVHTYDEHSE QVNCCHFTNS SHHLLLATGS
     SDCFLKLWDL NQKECRNTMF GHTNSVNHCR FSPDDKLLAS CSADGTLKLW DATSANERKS
     INVKQFFLNL EDPQEDMEVI VKCCSWSADG ARIMVAAKNK IFLFDIHTSG LLGEIHTGHH
     STIQYCDFSP QNHLAVVALS QYCVELWNTD SRSKVADCRG HLSWVHGVMF SPDGSSFLTS
     SDDQTIRLWE TKKVCKNSAV MLKQEVDVVF QENEVMVLAV DHIRRLQLIN GRTGQIDYLT
     EAQVSCCCLS PHLQYIAFGD ENGAIEILEL VNNRIFQSRF QHKKTVWHIQ FTADEKTLIS
     SSDDAEIQVW NWQLDKCIFL RGHQETVKDF RLLKNSRLLS WSFDGTVKVW NIITGNKEKD
     FVCHQGTVLS CDISHDATKF SSTSADKTAK IWSFDLLLPL HELRGHNGCV RCSAFSVDST
     LLATGDDNGE IRIWNVSNGE LLHLCAPLSE EGAATHGGWV TDLCFSPDGK MLISAGGYIK
     WWNVVTGESS QTFYTNGTNL KKIHVSPDFK TYVTVDNLGI LYILQTLE
//
